1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation

Gorde:

Xehetasun bibliografikoak
Egile Nagusiak:	Martin Reck, Alexander I. Spira, Benjamin Besse, Jennifer Moriatis Wolf, Ferdinandos Skoulidis, Hossein Borghaei, Kōichi Goto, K. Park, Frank Griesinger, Enriqueta Felip, Michael Boyer, Carlos H. Barrios, Glenwood Goss, Hui Yang, Cynthia Obiozor, Suresh S. Ramalingam
Formatua:	Artigo
Hizkuntza:	ingelesa
Argitaratua:	2020
Sarrera elektronikoa:	https://doi.org/10.1016/j.annonc.2020.08.1730 http://www.annalsofoncology.org/article/S0923753420417260/pdf
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet